Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Uterine Corpus Leiomyosarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Sarcoma (608
)
Soft Tissue Sarcoma (395
)
Spindle Cell Sarcoma (93
)
Osteosarcoma (53
)
Leiomyosarcoma (52
)
Ewing Sarcoma (42
)
Fibrosarcoma (33
)
Rhabdomyosarcoma (29
)
Liposarcoma (23
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
Sarcoma (608
)
Soft Tissue Sarcoma (395
)
Spindle Cell Sarcoma (93
)
Osteosarcoma (53
)
Leiomyosarcoma (52
)
Ewing Sarcoma (42
)
Fibrosarcoma (33
)
Rhabdomyosarcoma (29
)
Liposarcoma (23
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
›
Associations
(22)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Uterine Corpus Leiomyosarcoma
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AZD5363
Sensitive: C3 – Early Trials
AZD5363
Sensitive
:
C3
AZD5363
Sensitive: C3 – Early Trials
AZD5363
Sensitive
:
C3
CD70 expression
Uterine Corpus Leiomyosarcoma
CD70 expression
Uterine Corpus Leiomyosarcoma
ARX305
Sensitive: C3 – Early Trials
ARX305
Sensitive
:
C3
ARX305
Sensitive: C3 – Early Trials
ARX305
Sensitive
:
C3
ER positive + PGR positive
Uterine Corpus Leiomyosarcoma
ER positive + PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
PALB2 deletion
Uterine Corpus Leiomyosarcoma
PALB2 deletion
Uterine Corpus Leiomyosarcoma
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
RAD51B deletion
Uterine Corpus Leiomyosarcoma
RAD51B deletion
Uterine Corpus Leiomyosarcoma
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
BRCA2 mutation
Uterine Corpus Leiomyosarcoma
BRCA2 mutation
Uterine Corpus Leiomyosarcoma
avelumab + talazoparib
Sensitive: C3 – Early Trials
avelumab + talazoparib
Sensitive
:
C3
avelumab + talazoparib
Sensitive: C3 – Early Trials
avelumab + talazoparib
Sensitive
:
C3
BRCA1 mutation
Uterine Corpus Leiomyosarcoma
BRCA1 mutation
Uterine Corpus Leiomyosarcoma
avelumab + talazoparib
Sensitive: C3 – Early Trials
avelumab + talazoparib
Sensitive
:
C3
avelumab + talazoparib
Sensitive: C3 – Early Trials
avelumab + talazoparib
Sensitive
:
C3
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
lorlatinib
Sensitive: C4 – Case Studies
lorlatinib
Sensitive
:
C4
lorlatinib
Sensitive: C4 – Case Studies
lorlatinib
Sensitive
:
C4
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
pazopanib
Resistant: C4 – Case Studies
pazopanib
Resistant
:
C4
pazopanib
Resistant: C4 – Case Studies
pazopanib
Resistant
:
C4
BRCA2 mutation
Uterine Corpus Leiomyosarcoma
BRCA2 mutation
Uterine Corpus Leiomyosarcoma
PARP inhibitor
Sensitive: D – Preclinical
PARP inhibitor
Sensitive
:
D
PARP inhibitor
Sensitive: D – Preclinical
PARP inhibitor
Sensitive
:
D
ATRX mutation
Uterine Corpus Leiomyosarcoma
ATRX mutation
Uterine Corpus Leiomyosarcoma
BAY 1895344
Sensitive: D – Preclinical
BAY 1895344
Sensitive
:
D
BAY 1895344
Sensitive: D – Preclinical
BAY 1895344
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login